Clincosm LogoSign in Get a demo

Proper Dosage of Ketamine in Intravenous Regional Anesthesia

Sponsor
University Health Network, Toronto (Other)
Overall Status
Unknown status
CT.gov ID
NCT00221871
Collaborator
(none)
1
Location
12
Duration (Months)

Study Details

Study Description

Brief Summary

Ketamine added to Lidocaine can increase duration of pain relief following intraveonous regional anesthesia (IVRA). The purpose of this dose response study is to determine the minimum effective dosage of intravenous Ketamine, added to 3 mg/kg of Lidocaine. We anticipate that one dosage will provide us with the proper balance between sufficient anesthesia and minimal side effects.

Condition or Disease Intervention/Treatment Phase
  • Drug: Different dosages of Ketamine
 N/A

Study Design

Study Type:
Interventional
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single
Primary Purpose:
Treatment
Official Title:
Proper Dosage of Intravenous Ketamine When Used as an Adjuvant to Lidocaine in Intravenous Regional Anesthesia (IVRA).
Study Start Date :
Jan 1, 2004
Study Completion Date :
Jan 1, 2005

Outcome Measures

Primary Outcome Measures

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 70 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:

    1. Age: 18-70

    2. Weight: 50-100 kg

    3. ASA: I, II, III

    4. Carpal tunnel syndrome surgery, tenolysis, ganglion removal or any peripheral hand surgery that can be done by IVRA.

    Exclusion Criteria:

    1. Contraindication to IVRA such as sickle cell disease.

    2. Any known hypersensitivity reaction to Ketamine.

    3. History of chronic pain or regular medication with analgesics.

    4. History of opioid dependence.

    5. Drug of alcohol abuse.

    6. Psychiatric disorder.

    7. Allergy to acetaminophen or codeine

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 University Health Network Toronto Ontario Canada M5T2S8

    Sponsors and Collaborators

    • University Health Network, Toronto

    Investigators

    • Principal Investigator: Colin McCartney, MD, University Health Network, Toronto

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    , ,
    ClinicalTrials.gov Identifier:
    NCT00221871
    Other Study ID Numbers:
    • UHN02-0233-A
    First Posted:
    Sep 22, 2005
    Last Update Posted:
    Oct 11, 2006
    Last Verified:
    Sep 1, 2005
    Additional relevant MeSH terms:
    Ketamine

    Study Results

    No Results Posted as of Oct 11, 2006